Literature DB >> 1651083

Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.

J E Souness1, C M Carter, B K Diocee, G A Hassall, L J Wood, N C Turner.   

Abstract

Experiments have been performed to characterize guinea-pig peritoneal eosinophil cyclic nucleotide phosphodiesterase (PDE) activity and establish whether it is involved in regulating superoxide (.O2-) generation. Eosinophils were found to contain a predominantly membrane-bound cAMP PDE(s) (92.5 +/- 2.4% of total activity) which was resistant to solubilization with Triton X-100 (1%). This particulate PDE exhibited complex kinetics (Km = 1.3 and 31.4 microM) and was unaffected by cGMP (IC50 greater than 100 microM) or CaCl2 (2 mM) + calmodulin (10 units/mL). Little cGMP PDE activity was detected in either the soluble or particulate fractions. Inhibitors of the Ro-20-1724-inhibited (Type IV) cAMP PDE, namely Ro-20-1724 (IC50 = 0.92 +/- 0.43 microM), rolipram (IC50 = 0.20 +/- 0.04 microM) and denbufylline (IC50 = 0.20 +/- 0.01 microM), potently inhibited the particulate cAMP PDE, as did the non-selective inhibitors trequinsin (IC50 = 0.11 +/- 0.02 microM) and AH-21-132 (IC50 = 2.57 +/- 0.02 microM). Eosinophil cAMP PDE was resistant to SK&F 94120 (IC50 greater than 1000 microM), the cGMP-inhibited (Type III) cAMP PDE inhibitor, and the cGMP PDE (Type I) inhibitor, zaprinast, was only weakly active (IC50 = 35.33 +/- 10.74 microM). .O2- release from resting cells was potently inhibited by rolipram (IC50 = 0.05 +/- 0.03 microM) and denbufylline (IC50 = 0.06 +/- 0.04 microM) but surprisingly, in view of its potent cAMP PDE inhibitory activity, was only weakly decreased by trequinsin (IC50 = 8.0 +/- 2.7 microM). AH-21-132 (IC50 greater than 10 microM), SK&F 94120 (IC50 greater than 10 microM) and zaprinast (IC50 greater than 10 microM) were without effect. Rolipram and denbufylline alone exerted little effect on cAMP in intact cells but, in the presence of 10 microM isoprenaline, potently increased intracellular accumulation (EC50 = 0.45 +/- 0.16 and 0.28 +/- 0.08 microM, respectively). Trequinsin and AH-21-132 only weakly enhanced isoprenaline-stimulated cAMP accumulation. Although it induced a marked rise in cAMP only in the presence of isoprenaline, rolipram (50 microM) alone was able to increase the activity ratio of cAMP-dependent protein kinase from 0.24 to 0.84. The results suggest that Ro-20-1724-inhibited cAMP PDE plays a role in regulating eosinophil .O2- generation. The poor correlation between the PDE inhibitory actions of certain compounds and their effectiveness in elevating cAMP and inhibiting .O2- suggests the existence of a barrier impeding access to the enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651083     DOI: 10.1016/0006-2952(91)90056-b

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors:  K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.

Authors:  S-L Catherine Jin; Sho Goya; Susumu Nakae; Dan Wang; Matthew Bruss; Chiaoyin Hou; Dale Umetsu; Marco Conti
Journal:  J Allergy Clin Immunol       Date:  2010-11-03       Impact factor: 10.793

4.  Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.

Authors:  J E Souness; M E Villamil; L C Scott; A Tomkinson; M A Giembycz; D Raeburn
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.

Authors:  N C Turner; J Lamb; A Worby; K J Murray
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

Authors:  H Tenor; A Hatzelmann; M K Church; C Schudt; J K Shute
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 10.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.